On Apr. 6, 2020, OncoSec Medical announced that Providence Cancer Institute, a part of Providence St. Joseph Health , is pursuing a first-in-human Phase 1 clinical trial of OncoSec’s novel DNA-encodable, investigational vaccine, CORVax12, which is designed to act as a prophylactic vaccine to prevent COVID-19.

CORVax12 consists of OncoSec’s existing product candidate, TAVOﾙ (interleukin-12 or “IL-12” plasmid), in combination with an immunogenic component of the SARS-CoV-2 virus recently developed by researchers at the National Institute of Allergy and Infectious Diseases and licensed to OncoSec on a non-exclusive basis.